HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 9, September 2016 – Infectious Diseases       » Curcumin Derivatives May Prevent Alzheimer's Disease by Promoting Amyloid-β Clearance       » Varian Chosen to Equip First Government Owned Proton Centre in China       » Medtronic and SingHealth Collaborate on a Centre of Excellence to Fight Diabetes       » NCCS Awards Contract for Proton Beam Therapy System to Hitachi Asia      
BIOBOARD - UNITED STATES
Cancer Genetics selected by Gilead Sciences, Inc. to provide clinical trial services for chronic lymphocytic leukemia
Cancer Genetics, Inc. (CGI) announces that it has been chosen by Gilead Sciences Inc. (Gilead) to provide clinical trial services and molecular profiling of chronic lymphocytic leukemia (CLL) patients. The trials cover both national and international locations. CGI will leverage its SelectOne™ program that includes proprietary genomic assays in CLL, data and logistics management, and comprehensive CLIA- and CAP-accredited clinical laboratory testing. The ongoing studies consist of testing across several methodologies, including flow cytometry, FISH, and molecular diagnostics assays including mutational analyses of IGHV, TP53, NOTCH1, and CGI's proprietary array-CGH assay for mature B-cell neoplasm, MatBA®-CLL/SLL.

Targeted therapies have the potential of improving the lives of cancer patients and providing them with better treatment outcome. CGI's SelectOne™ offering empowers biotech and pharma companies like Gilead to achieve their goals in oncology clinical trials through the use of CGI's comprehensive oncology focused menu and proprietary microarrays.

CGI expects the trials to continue for the next several years, and may potentially enable an expedited and more efficient development timeline based on improved patient stratification. CGI also offers comprehensive CLL testing to cancer centers, oncologists and community hospitals under its CLL CompleteSM offering. This includes the assessment of ZAP-70, CD38, mutational status of IGHV, TP53 and SF3B1, genomic alterations by FISH and by a proprietary genomic microarray – MatBA®-CLL/SLL which includes a comprehensive report stratifying the risk and potential outcome, to guide disease and patient management. CLL is a clinically heterogeneous disease and the most common form of leukemia in the Western Hemisphere. It is estimated that in the United States there is a new case diagnosed every forty minutes and there are over 110,000 people living with CLL.

Click here for the complete issue.

NEWS CRUNCH  
news Enterprise meets technology: More than 300 enabling innovations showcased at TechInnovation
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Orthopaedics
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy